Evidence map›Paper›PMID 42387550›Full record

ArticleJournal of nanobiotechnology2026

ISL@mTOMV nanoparticles: a promising approach for VM-targeted therapy in breast cancer.

Chengxiao Fu, Zhimin Li, Bowen Tang, Zhongxiang Fan, Yongmei Luo, Xinyu Yi, Bing Shu, Ziliang Liu, Baohong Jiang, Yuehua Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chengxiao Fu *Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Zhimin Li *Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Bowen TangDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Zhongxiang FanDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Yongmei LuoDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Xinyu YiDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Bing ShuDepartment of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Ziliang LiuDepartment of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China.
Baohong JiangDepartment of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China. jiangbaohongstudy@126.com.
Yuehua LiDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan Province, China. liyuehua2020@stu.usc.edu.cn.

Funding

Clinical Medical Research "4310" Program of the University of South China No.20224310NHYCG07Hunan Provincial Health Commission No.B202303109577Hunan Provincial Health Commission No. D202303109450Interdisciplinary Research Program in Medicine and Engineering, the First Affiliated Hospital of University of South China IRP-M&E-2025-05Natural Science Foundation of China No.82404928Natural Science Foundation of Hunan Province No.2022JJ40393Natural Science Foundation of Hunan Province No.2023JJ40588
6 · The paper itself

Abstract

Vasculogenic mimicry (VM) in breast cancer is recognized as an important non-endothelium-dependent vascular mechanism that promotes tumor invasiveness, survival, and metastatic potential; however, effective and specific intervention strategies remain limited. In this study, we innovatively constructed a nanodelivery system based on hybrid membranes derived from bacterial outer membrane vesicles and breast cancer cell membranes, termed mTOMV, and loaded it with the natural flavonoid isoliquiritigenin (ISL) to enhance targeted antitumor activity. ISL@mTOMV nanoparticles exhibited a uniform spherical morphology, favorable stability, and good biocompatibility. In vitro experiments demonstrated that ISL@mTOMV significantly inhibited the proliferation, migration, and invasion of MDA-MB-231 and MCF-7 breast cancer cells, while promoting tumor cell apoptosis. Mechanistically, ISL@mTOMV markedly reduced the expression of ACLY, H3K27ac, and SMAD5 and suppressed the activity of the TGF-β/SMAD signaling pathway. In vivo experiments further confirmed that ISL@mTOMV inhibited ACLY-mediated H3K27 acetylation, attenuated SMAD5 transcriptional activation, and blocked TGF-β/SMAD signaling, thereby significantly suppressing VM formation in breast cancer. Collectively, this study proposes a highly biocompatible and tumor-targeted nanotherapeutic strategy, providing a new technical approach and potential translational value for VM intervention in breast cancer.

Indexed as

Antineoplastic AgentsBreast NeoplasmsChalconesNanoparticlesNeovascularization, PathologicAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationFemaleHumansMCF-7 CellsMDA-MB-231 CellsMiceMice, Inbred BALB CAntineoplastic AgentsChalconesisoliquiritigeninTransforming Growth Factor betaBreast CancerHybrid Membrane NanoparticlesIsoliquiritigeninOuter Membrane VesiclesTransforming Growth Factor Beta/SMAD Signaling PathwayVasculogenic Mimicry

Identifiers

PMID42387550
PMCPMC13595736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.